Idiopathic genital pyoderma gangrenosum successfully treated with infliximab biosimilar

Authors

  • Ashba Nasir Cheema Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore
  • Hira Tariq Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore
  • Javeria Bushra Touqir Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore
  • Saelah Batool Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore
  • Uzma Amin Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore
  • Alina Abbass Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore
  • Faria Asad Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore

Keywords:

Pyoderma gangrenosum, Neutrophilic dermatoses, Infliximab biosimilar

Abstract

Pyoderma gangrenosum (PG) is an atypical, chronic, sterile pustular rapidly progressing ulcerating condition categorized as neutrophilic dermatosis, whose etiology remains a mystery. Other ulcerating wounds can also imitate PG, and cause a difficulty in diagnosing the condition and starting appropriate management. In our case, we had a 22-years old female with genital PG. PG has no specific clinical, histologic or lab findings, therefore diagnosis is based on exclusion of all other diagnostic possibilities, especially infectious causes. The clinical history, examination findings and histopathology confirmed it as genital pyoderma gangrenosum. Treatment with subcutaneous infliximab biosimilar led to complete healing. Key Words: Pyoderma gangrenosum, neutrophilic dermatosis

Author Biography

Faria Asad, Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore

Prof. and Head of Department

References

Schmieder SJ, Krishnamurthy K. Pyoderma Gangrenosum. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482223/

Chen B, Li W, Qu B. Practical aspects of the diagnosis and management of pyoderma gangrenosum. Front Med (Lausanne). 2023;10:1134939.

Łyko M, Ryguła A, Kowalski M, Karska J, Jankowska-Konsur A. The Pathophysiology and Treatment of Pyoderma Gangrenosum-Current Options and New Perspectives. Int J Mol Sci. 2024;25(4):2440.

Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581–5.

Marzano AV, Trevisan V, Lazzari R, Crosti C. Pyoderma gangrenosum: study of 21 patients and proposal of a ‘clinicotherapeutic classification’. J Dermatolog Treat. 2011;22(5):254–260.

Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152:1059–61.

Wolff K, Stingl G. Pyoderma gangrenosum. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick's Dermatology in General Medicine. New York: McGraw-Hill. 2003;6(1):969-76.

Mikail M, Wilson A. Infliximab treatment for large, multifocal, abdominal pyoderma gangrenosum associated with ulcerative colitis: A case report. SAGE Open Med Case Rep. 2020;8:2050313X20964113.

Downloads

Published

2024-12-31

How to Cite

1.
Ashba Nasir Cheema, Hira Tariq, Javeria Bushra Touqir, Batool S, Uzma Amin, Abbass A, Asad F. Idiopathic genital pyoderma gangrenosum successfully treated with infliximab biosimilar. J Pak Assoc Dermatol [Internet]. 2024Dec.31 [cited 2025Feb.16];34(4 Suppl.):S125-S128. Available from: https://jpad.com.pk/index.php/jpad/article/view/2987

Most read articles by the same author(s)

1 2 3 4 5 6 > >>